Arthritis and C-fms for the Treatment of Rheumatoid Sb1578, a Novel Inhibitor of Jak2, Flt3

[1]  J. Wood,et al.  Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthr , 2012, Journal of medicinal chemistry.

[2]  A. Poulsen,et al.  SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies , 2011, Leukemia.

[3]  M. Bokarewa,et al.  Inhibition of fms‐like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation , 2011, Journal of leukocyte biology.

[4]  H. Leffers,et al.  Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry , 2011, Annals of the rheumatic diseases.

[5]  P. Emery,et al.  New therapies in the management of rheumatoid arthritis , 2011, Current opinion in rheumatology.

[6]  P. Dobrzanski,et al.  A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis , 2011, Arthritis research & therapy.

[7]  G. Guyatt,et al.  Adverse effects of biologics: a network meta-analysis and Cochrane overview. , 2011, The Cochrane database of systematic reviews.

[8]  J. Kremer,et al.  Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. , 2010, Best practice & research. Clinical rheumatology.

[9]  J. Fonseca,et al.  Neutrophils in rheumatoid arthritis: More than simple final effectors. , 2010, Autoimmunity reviews.

[10]  J. Fridman,et al.  Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050 , 2010, The Journal of Immunology.

[11]  Stanley B. Cohen,et al.  Kinase inhibitors: a new approach to rheumatoid arthritis treatment , 2010, Current opinion in rheumatology.

[12]  Alisa Opar,et al.  Kinase inhibitors attract attention as oral rheumatoid arthritis drugs , 2010, Nature Reviews Drug Discovery.

[13]  W. Robinson,et al.  c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis , 2010, Arthritis research & therapy.

[14]  N. Walsh,et al.  Bone remodeling in rheumatic disease: a question of balance , 2010, Immunological reviews.

[15]  G. Firestein,et al.  Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis , 2010, Immunological reviews.

[16]  E. Ruderman,et al.  Anti-interleukin-6 therapy in rheumatoid arthritis. , 2010, Bulletin of the NYU hospital for joint diseases.

[17]  J. Greenberg,et al.  Dendritic cells as targets for therapy in rheumatoid arthritis , 2009, Nature Reviews Rheumatology.

[18]  J. Singh,et al.  Anakinra for Rheumatoid Arthritis: A Systematic Review , 2009, The Journal of Rheumatology.

[19]  M. Khraishi.  Comparative Overview of Safety of the Biologics in Rheumatoid Arthritis , 2009, The Journal of Rheumatology.

[20]  J. O’Shea,et al.  Janus kinases in immune cell signaling , 2009, Immunological reviews.

[21]  S. Foster,et al.  Intra-Articular Fms-Like Tyrosine Kinase 3 Ligand Expression Is a Driving Force in Induction and Progression of Arthritis , 2008, PloS one.

[22]  T. Brodie,et al.  Effects of the cFMS Kinase Inhibitor 5-(3-Methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in Normal and Arthritic Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.

[23]  K. Vandenbroeck,et al.  Signalling, inflammation and arthritis: crossed signals: the role of interleukin (IL)-12, -17, -23 and -27 in autoimmunity. , 2008, Rheumatology.

[24]  J. O’Shea,et al.  Therapeutic targeting of Janus kinases , 2008, Immunological reviews.

[25]  L. Audoly,et al.  Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis , 2008, Arthritis research & therapy.

[26]  I. Serizawa,et al.  The orally‐active and selective c‐Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen‐induced arthritis mouse model , 2008, European journal of immunology.

[27]  P. Kostenuik,et al.  The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis. , 2008, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[28]  C. Bingham.  Emerging therapeutics for rheumatoid arthritis. , 2008, Bulletin of the NYU hospital for joint diseases.

[29]  Y. Iwakura,et al.  Anti‐type II collagen antibody accelerates arthritis via CXCR2‐expressing cells in IL‐1 receptor antagonist‐deficient mice , 2007, European journal of immunology.

[30]  I. McInnes,et al.  Emerging cytokine targets in rheumatoid arthritis , 2007, Current opinion in rheumatology.

[31]  P. Calabresi,et al.  Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Malcolm D. Smith,et al.  The Jak-STAT pathway in rheumatoid arthritis. , 2005, The Journal of rheumatology.

[33]  A. Zwinderman,et al.  Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[34]  A. Bendele,et al.  Development of a rapid screen for detecting and differentiating immunomodulatory vs. anti-inflammatory compounds in rats , 1991, Agents and Actions.

[35]  Yuka Kanno,et al.  Signaling by IL‐12 and IL‐23 and the immunoregulatory roles of STAT4 , 2004, Immunological reviews.

[36]  A. A. Drosos,et al.  Epidemiology of rheumatoid arthritis. , 2004, Autoimmunity reviews.

[37]  K. Shuai,et al.  Regulation of JAK–STAT signalling in the immune system , 2003, Nature Reviews Immunology.

[38]  I. Weissman,et al.  Flt3 Ligand Regulates Dendritic Cell Development from Flt3+ Lymphoid and Myeloid-committed Progenitors to Flt3+ Dendritic Cells In Vivo , 2003, The Journal of experimental medicine.

[39]  T. Chambers,et al.  FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. , 2001, Blood.

[40]  Paul M. Allen,et al.  Essential Role of Neutrophils in the Initiation and Progression of a Murine Model of Rheumatoid Arthritis1 , 2001, The Journal of Immunology.

[41]  G. Panayi,et al.  Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.

[42]  F. Belardelli,et al.  Loss of CCR2 expression and functional response to monocyte chemotactic protein (MCP-1) during the differentiation of human monocytes: role of secreted MCP-1 in the regulation of the chemotactic response. , 1999, Blood.

[43]  Ranjeny Thomas,et al.  Dendritic cells and the pathogenesis of rheumatoid arthritis , 1999, Journal of leukocyte biology.

[44]  L. Moreland.  Inhibitors of tumor necrosis factor for rheumatoid arthritis. , 1999, The Journal of rheumatology. Supplement.

[45]  垣内 史堂.  私の愛読誌 : Journal of Immunology , 1999 .

[46]  Z Domljan,et al.  Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. , 1998, Arthritis and rheumatism.

[47]  R. Andreesen,et al.  Retinoic acid inhibits monocyte to macrophage survival and differentiation. , 1998, Blood.

[48]  W. B. van den Berg,et al.  Dual role of IL-12 in early and late stages of murine collagen type II arthritis. , 1997, Journal of immunology.

[49]  A. Flanagan,et al.  Macrophage colony-stimulating factor induces substantial osteoclast generation and bone resorption in human bone marrow cultures. , 1996, Blood.

[50]  R. Maini,et al.  The Role of Cytokines in Rheumatoid Arthritis , 1996, Journal of the Royal College of Physicians of London.

[51]  Hidemi,et al.  [Macrophage colony-stimulating factor in patients with rheumatoid arthritis]. , 1995, Nihon Ika Daigaku zasshi.

[52]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[53]  N. Udagawa,et al.  Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. , 1993, The Journal of clinical investigation.

[54]  S. Weiss.  Tissue destruction by neutrophils. , 1989, The New England journal of medicine.

[55]  F. Houssiau,et al.  Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. , 1988, Arthritis and rheumatism.